In vitro activity of solithromycin and its metabolites, CEM-214 and N-acetyl-CEM-101, against 100 clinical Ureaplasma spp. isolates compared with azithromycin

International Journal of Antimicrobial Agents

Volumn 46, Issue 3, 2015, Pages 319-324

  Furfaro, Lucy L ^a   Spiller, O Brad ^b   Keelan, Jeffrey A ^a   Payne, Matthew S ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Antibiotic; Azithromycin; Minimum inhibitory concentration; Preterm birth; Solithromycin; Ureaplasma

Indexed keywords

AZITHROMYCIN; CEM 214; DRUG METABOLITE; N ACETYL CEM 101; SOLITHROMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; MACROLIDE; TRIAZOLE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; AUSTRALIA; BACTERIUM ISOLATE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG POTENCY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; UNITED KINGDOM; UREAPLASMA; ANTIBIOTIC RESISTANCE; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; GREAT BRITAIN; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEWBORN; PREGNANCY; UREAPLASMA INFECTION;

ANTI-BACTERIAL AGENTS; AUSTRALIA; AZITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; GREAT BRITAIN; HUMANS; INFANT, NEWBORN; MACROLIDES; MICROBIAL SENSITIVITY TESTS; PREGNANCY; TRIAZOLES; UREAPLASMA; UREAPLASMA INFECTIONS;

EID: 84940447736     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.04.015     Document Type: Article

References (30)

1. H. Blencowe, S. Cousens, D. Chou, M. Oestergaard, L. Say, A.B. Moller, and et al. Born Too Soon Preterm Birth Action Group. Born too soon: the global epidemiology of 15 million preterm births Reprod Health 10 Suppl 1 2013 S2
2. R.L. Goldenberg, J.F. Culhane, J.D. Iams, and R. Romero Epidemiology and causes of preterm birth Lancet 371 2008 75 84
3. M.S. Payne, and S. Bayatibojakhi Exploring preterm birth as a polymicrobial disease: an overview of the uterine microbiome Front Immunol 5 2014 595
4. M.J. Czikk, F.P. McCarthy, and K.E. Murphy Chorioamnionitis: from pathogenesis to treatment Clin Microbiol Infect 17 2011 1304 1311
5. J. Lowe, W.J. Watkins, M.O. Edwards, O.B. Spiller, E. Jacqz-Aigrain, S.J. Kotecha, and et al. Association between pulmonary Ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis Pediatr Infect Dis J 33 2014 697 702
6. M.C. Shepard Ureaplasma urealyticum. Overview with emphasis on fetal and maternal infections Ann N Y Acad Sci 549 1988 48 55
7. J.S. Dashe, and L.C. Gilstrap Antibiotic use in pregnancy Obstet Gynecol Clin North Am 24 1997 617 629
8. J.T. Andersen, M. Petersen, E. Jimenez-Solem, K. Broedbaek, N.L. Andersen, C. Torp-Pedersen, and et al. Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a register based nationwide cohort study PLOS ONE 8 2013 e53327
9. T. Heikkinen, K. Laine, P.J. Neuvonen, and U. Ekblad The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin BJOG 107 2000 770 775
10. S. Kenyon, K. Pike, D.R. Jones, P. Brocklehurst, N. Marlow, A. Salt, and et al. Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial Lancet 372 2008 1310 1318
11. S.J. Dando, I. Nitsos, G.R. Polglase, J.P. Newnham, A.H. Jobe, and C.L. Knox Ureaplasma parvum undergoes selection in utero resulting in genetically diverse isolates colonizing the chorioamnion of fetal sheep Biol Reprod 90 2014 27
12. L. Xiao, D.M. Crabb, L.B. Duffy, V. Paralanov, J.I. Glass, D.L. Hamilos, and et al. Mutations in ribosomal proteins and ribosomal RNA confer macrolide resistance in human Ureaplasma spp Int J Antimicrob Agents 37 2011 377 379
13. E.J. Diner, and C.S. Hayes Recombineering reveals a diverse collection of ribosomal proteins L4 and L22 that confer resistance to macrolide antibiotics J Mol Biol 386 2009 300 315
14. W. Rodgers, A.D. Frazier, and W.S. Champney Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae Antimicrob Agents Chemother 57 2013 1632 1637
15. L.N. Woosley, M. Castanheira, and R.N. Jones CEM-101 activity against Gram-positive organisms Antimicrob Agents Chemother 54 2010 2182 2187
16. J.M. Rybak, K.E. Barber, and M.J. Rybak Current and prospective treatments for multidrug-resistant Gram-positive infections Expert Opin Pharmacother 14 2013 1919 1932
17. J.G. Still, J. Schranz, T.P. Degenhardt, D. Scott, P. Fernandes, M.J. Gutierrez, and et al. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects Antimicrob Agents Chemother 55 2011 1997 2003
18. D. Oldach, K. Clark, J. Schranz, A. Das, J.C. Craft, D. Scott, and et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia Antimicrob Agents Chemother 57 2013 2526 2534
19. J.A. Keelan, M.W. Kemp, M.S. Payne, D. Johnson, S.J. Stock, M. Saito, and et al. Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model Antimicrob Agents Chemother 58 2014 447 454
20. J.A. Keelan, and K. Pugazhenthi Trans-placental passage and anti-inflammatory effects of solithromycin in the human placenta Placenta 35 2014 1043 1048
21. M.L. Beeton, V.J. Chalker, N.C. Maxwell, S. Kotecha, and O.B. Spiller Concurrent titration and determination of antibiotic resistance in Ureaplasma species with identification of novel point mutations in genes associated with resistance Antimicrob Agents Chemother 53 2009 2020 2027
22. K.B. Waites, L.B. Duffy, C.M. Bebear, A. Matlow, D.F. Talkington, G.E. Kenny, and et al. Standardized methods and quality control limits for agar and broth microdilution susceptibility testing of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum J Clin Microbiol 50 2012 3542 3547
23. M.S. Payne, T. Tabone, M.W. Kemp, J.A. Keelan, O.B. Spiller, and J.P. Newnham High-resolution melt PCR analysis for genotyping of Ureaplasma parvum isolates directly from clinical samples J Clin Microbiol 52 2014 599 606
24. J. Yi, B.H. Yoon, and E.C. Kim Detection and biovar discrimination of Ureaplasma urealyticum by real-time PCR Mol Cell Probes 19 2005 255 260
25. Y. Miura, M.S. Payne, J.A. Keelan, A. Noe, S. Carter, R. Watts, and et al. Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection Antimicrob Agents Chemother 58 2014 5413 5420
26. K.B. Waites, D.M. Crabb, and L.B. Duffy Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101 Antimicrob Agents Chemother 53 2009 2139 2141
27. R. Capoccia, G. Greub, and D. Baud Ureaplasma urealyticum, Mycoplasma hominis and adverse pregnancy outcomes Curr Opin Infect Dis 26 2013 231 240
28. D.E. Pereira, T. Degenhardt, and P. Fernandes Comparison of CEM-101 metabolism in mice, rats, monkeys and humans 50th Interscience conference on antimicrobial agents and chemotherapy (ICAAC) 12-15 September 2010 ASM Press Boston, MA/Washington, DC
29. R.M. Viscardi Ureaplasma species: role in neonatal morbidities and outcomes Arch Dis Child Fetal Neonatal Ed 99 2014 F87 F92
30. M.A. Martínez, A. Ovalle, A. Santa-Cruz, B. Barrera, R. Vidal, and R. Aguirre Occurrence and antimicrobial susceptibility of Ureaplasma parvum (Ureaplasma urealyticum biovar 1) and Ureaplasma urealyticum (Ureaplasma urealyticum biovar 2) from patients with adverse pregnancy outcomes and normal pregnant women Scand J Infect Dis 33 2001 604 610